Abstract
“Tissue” or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca2+-dependent posttranslational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntingtons (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.
Current Pharmaceutical Design
Title: Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Volume: 14 Issue: 3
Author(s): Mauro Piacentini, Walter Malorni, Maria Grazia Farrace and Carlo Rodolfo
Affiliation:
Abstract: “Tissue” or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca2+-dependent posttranslational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntingtons (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Piacentini Mauro, Malorni Walter, Farrace Grazia Maria and Rodolfo Carlo, Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection, Current Pharmaceutical Design 2008; 14 (3) . https://dx.doi.org/10.2174/138161208783413220
DOI https://dx.doi.org/10.2174/138161208783413220 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mononuclear Cell Recruitment and Inflammation in Atherosclerosis
Vascular Disease Prevention (Discontinued) Correlation of Alzheimer-like Tau Hyperphosphorylation and fMRI Bold Intensity
Current Alzheimer Research The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Efficacy of Zofenopril Alone or in Combination with Hydrochlorothiazide in Patients with Kidney Dysfunction
Current Clinical Pharmacology Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism Therapeutic Strategies Targeting Endothelial Function in Humans:Clinical Implications
Current Vascular Pharmacology Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry Anti-Aging Drugs – Prospect of Longer Life?
Current Medicinal Chemistry Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Importance of Humanized Yeast to Better Understand the Role of Bcl-2 Family in Apoptosis: Finding of Novel Therapeutic Opportunities
Current Pharmaceutical Design The Effect of Polyphenol Consumption on Blood Pressure
Mini-Reviews in Medicinal Chemistry Control of Menopausal Transition through Physical Exercises
Current Women`s Health Reviews Cell Responses to Oxidative Stressors
Current Pharmaceutical Design Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Opposite Effects of Two-Derived Antioxidants from Physalis pubescens L. on Hepatocellular Carcinoma Cell Line Malhavu
Current Pharmaceutical Biotechnology Pharmacologic Methods to Reduce Postoperative Bleeding in Adult Cardiac Surgery. A Mini-review
Current Pharmaceutical Design Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine